Efficacy of lianhuaqingwen granules in the management of chronic rhinosinusitis without nasal polyps

Lin, Lin; Dai, Fei; Ren, Guowu; Wei, Jinjin; Chen, Zheng; Tang, Xinyue

doi:10.1016/j.amjoto.2019.102311

Cited by 18 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacological experiments have indicated that a high dosage of Lianhua Qingwen alters the effectiveness of cyclooxygenase-2 in the arachidonic acid metabolic pathway and decreases decrease virus replication, producing significant improvements in lung inflammation [ 69 ]. It was recently reported that Lianhua Qingwen plays a significant role in the treatment of pneumonia by significantly reducing pathological changes, which might be correlated with the levels of enzymes regulated by Lianhua Qingwen, such as glutathione peroxidase, lactate dehydrogenase, superoxide dismutase, and malonaldehyde [ 65 ]. Previous studies reviewed historical records and prevention measures against SARS, H1N1 influenza, and Middle East respiratory syndrome (MERS) and reported that traditional Chinese medicine might be an alternative for the prevention and treatment of COVID-19 pneumonia [ 70 – 73 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID‐19 Pneumonia: A Meta‐Analysis

Liang

Gong

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background and Objectives. Lianhua Qingwen is a traditional Chinese medicine, which has been reported to be effective in the treatment of pneumonia. However, no consensus has been reached; therefore, we aimed to provide reliable assessments of common pneumonia and COVID-19 pneumonia. Methods. Seven English and Chinese databases were used to search for qualified experimental studies as of July 27, 2020. All data were extracted directly from the included studies, and no special conversion formula was used. The weighted mean difference (WMD), 95% confidence interval (CI), and odds ratio (OR) were used for evaluation. Results. Forty-two studies involving 3793 subjects met the qualification criteria. For common pneumonia, a short duration of flu-like symptoms (WMD = −1.81, 95% CI = −2.12 to −1.50, P < 0.001), sputum (WMD = −1.10, 95% CI = −1.50 to −0.70, P < 0.001), pulmonary rale (WMD = −2.03, 95% CI = −2.74 to −1.31, P < 0.001), pulmonary imaging improvement (WMD = −1.88, 95% CI = −2.28 to −1.47, P < 0.001), curative effect (OR = 3.65, 95% CI = 2.81 to 4.76, P < 0.001), and healing period (WMD = −1.68, 95% CI = −2.62 to −0.74, P < 0.001) were associated with the Lianhua Qingwen group; subgroup analysis based on flu-like symptoms showed statistically significant improvements in fever and cough. For COVID-19 pneumonia, improvements in flu-like symptoms (OR = 3.18, 95% CI = 2.36 to 4.29, P < 0.001), shortness of breath (OR = 10.62, 95% CI = 3.71 to 30.40, P < 0.001), curative effect (OR = 2.49, 95% CI = 1.76 to 3.53, P < 0.001), healing period (WMD = −2.06, 95% CI = −3.36 to −0.75, P = 0.002), and conversion of severe cases (OR = 0.46, 95% CI = 0.27 to 0.77, P = 0.003) were associated with the Lianhua Qingwen group; subgroup analysis indicated statistically significant improvements of fever, cough, fatigue, and muscle pain in the Lianhua Qingwen group compared to the conventional drug group. Regarding adverse reactions, no significant difference was detected for common pneumonia (OR = 0.75, 95% CI = 0.54 to 1.05, P = 0.097). Conclusions. Lianhua Qingwen combined with conventional drugs may be a promising therapy for treating common pneumonia and COVID-19 pneumonia.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID‐19 Pneumonia: A Meta‐Analysis

Liang

Gong

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…In pulmonary oxidative lesions models, LHQW could significantly reduce pathological changes, including alveolar septum thickening, capillary congestion, interstitial edema, peripheral bronchial lymphocyte infiltration and neutrophils, the mechanism might be related to the levels of malonaldehyde, LDH, glutathione peroxidase, and super oxide dismutase were regulated by LHQW, which play significant role in pathogenesis of lung injury [10]. LHQW could inhibits the replication of SARS-COV-2 in vitro, and significantly reduced pro-inflammatory cytokines production (IL-6, TNF-α), which might mediate strong immune response or even cytokine storm [11].…”

Section: Lianhuaqingwen Protect Lung From Pneumonia Via Inhibiting Prmentioning

confidence: 97%

The potential insights of Traditional Chinese Medicine on treatment of COVID-19

Tong

et al. 2020

Chin Med

View full text Add to dashboard Cite

Corona Virus Disease 2019 (COVID-19) broke out in 2019 and spread rapidly around the world. There is still no specific antiviral therapy to the current pandemic. In China, historical records show that Traditional Chinese Medicine (TCM) is effective in prevention and enhancing the resistance to pandemic with unique insights. To fight with COVID-19, National Health and Commission of PRC has recommended some TCM in the guideline, such as HuoxiangZhengqi, LianhuaQingwen ShufengJiedu and XueBijing, and actually displayed a remarkable effect in clinical treatment strategic for COVID-19. We review studies to provide an in-depth understanding into the effect of TCM, and also introduce the possible mechanism involved in COVID-19 treatment.

show abstract

“…C. Li, et al Virus Research 286 (2020) 198073 2017) as well as other respiratory diseases, such as chronic rhinosinusitis (Lin et al, 2020a), chronic obstructive pulmonary disease (Dong et al, 2014), etc. LHQW can block the early stage of virus infection, impair the nuclear export of the viral RNP, and modulate immune responses during virus infection (Ding et al, 2017).…”

Section: Easy To Takementioning

confidence: 99%

Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection

Wang

Ren

2020

Virus Research

View full text Add to dashboard Cite

The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic. Up to now, numerous medicines have been applied or approved for the prevention and control of the virus infection. However, the efficiency of each medicine or combination is completely different or still unknown. In this review, we discuss the types, characteristics, antiviral mechanisms, and shortcomings of recommended candidate medicines for SARS-CoV-2 infection, as well as perspectives of the drugs for the disease treatment, which may provide a theoretical basis for drug screening and application.

show abstract

Efficacy of lianhuaqingwen granules in the management of chronic rhinosinusitis without nasal polyps

Cited by 18 publications

References 21 publications

Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID‐19 Pneumonia: A Meta‐Analysis

Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID‐19 Pneumonia: A Meta‐Analysis

The potential insights of Traditional Chinese Medicine on treatment of COVID-19

Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection

Contact Info

Product

Resources

About